Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) - Jounce Therapeutics, Inc

9 Mar 2023 11:22

RNS Number : 4654S
Redx Pharma plc
09 March 2023
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Jounce Therapeutics, Inc ("Jounce")

(d) Is the discloser the offeror or the offeree?

Offeree

(e) Date position held:

The latest practicable date prior to the disclosure

9 March 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes - Redx Pharma plc

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Jounce common shares of $0.001 par value per share ("Shares")

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

-

0

-

(2) Cash-settled derivatives:

 

0

-

0

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

-

0

-

TOTAL:

0

-

0

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Registered holder

Class

Number of Shares

Percentage shareholding (%)

Sidley Austin Master Pension Trust ("SAMP Trust")

Jounce common shares of $0.001 par value per share

2,968

0.00569234%

SA Investment Partnership IV LLC ("SAIP IV")

Jounce common shares of $0.001 par value per share

1,978

0.00379361%

 

The SAMP Trust is a benefit plan trust that holds certain assets of Sidley Austin LLP's U.S.-based retirement plans. SAIP IV is an employees' securities company whose members are current or former partners or senior staff members of Sidley Austin LLP (or trusts formed by such persons).

 

Sidley Austin LLP is acting as legal adviser to RedCo II Master Fund, L.P. and RM Special Holdings 3, LLC.

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

9 March 2023

Contact name:

Claire Solk, Group Company Secretary

Telephone number:

+44(0)1625 469900

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEFLFFLVIIAIIV
Date   Source Headline
4th Feb 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Feb 20206:27 pmRNSForm 8.3 - RedX Pharma PLC
3rd Feb 202011:45 amRNSForm 8.5 (EPT/RI)
30th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
28th Jan 20207:00 amRNSStatement re Rule 2.6 Extension
24th Jan 202011:05 amRNSHolding(s) in Company
24th Jan 20209:40 amRNSHolding(s) in Company
23rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
23rd Jan 20208:32 amRNSForm 8.3 - Redx Pharma plc
22nd Jan 20205:04 pmRNSPaul John Blackmore - Form 8.3 - RedX Pharma
22nd Jan 202012:49 pmRNSForm 8.3 - RedX Pharma PLC
22nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
21st Jan 20201:23 pmRNSResult of General Meeting
16th Jan 20209:25 amRNSForm 8.3 - Redx Pharma plc
15th Jan 20204:20 pmRNSForm 8.3 - Redx Pharma PLC
15th Jan 20203:17 pmRNSForm 8.3 - Redx Pharma Plc
15th Jan 20202:57 pmRNSForm 8.3 - Redx Pharma plc
10th Jan 20207:56 amRNSForm 8.3 - Redx Pharma plc
9th Jan 20202:14 pmRNSPublic Opening Position Disclosure
9th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
9th Jan 20207:00 amRNSRXC007 nominated as drug development candidate
7th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
6th Jan 20202:16 pmRNSForm 8.3 - Redx Pharma
6th Jan 202011:45 amRNSForm 8.5 (EPT/RI)
3rd Jan 20204:14 pmRNSPosting of Circular to Shareholders
3rd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
2nd Jan 20202:44 pmRNSForm 8.3 - Redx Pharma plc
2nd Jan 202012:57 pmGNWForm 8.3 - AXA INVESTMENT MANAGERS: Redx Pharma PLC
2nd Jan 202011:45 amRNSForm 8.5 (EPT/RI)
31st Dec 20197:00 amRNSLoan Capitalisation, GM Notice and Possible Offer
19th Nov 20197:00 amRNSRedx & Medicines Discovery Catapult awarded grant
7th Nov 20193:30 pmRNSHolding(s) in Company
23rd Sep 20197:00 amRNSRXC006 poster presentation at ERS Congress
19th Aug 20197:00 amRNSFirst cohort of patients dosed in RXC004 study
18th Jul 201910:24 amEQSHardman & Co Research: RedX Pharma (REDX): Pan-RAF agreement strengthens balance sheet
11th Jul 20191:41 pmEQSHardman & Co Research: Redx Pharma (REDX): Phase I trial resumed
10th Jul 20197:00 amRNSSale of pan-RAF inhibitor programme
10th Jun 20197:01 amRNSInterim Results for six months ended 31 March 2019
10th Jun 20197:00 amRNSShort-term Debt Funding Secured
3rd May 201911:34 amRNSUpdate on Plans to Strengthen Balance Sheet
29th Mar 20197:00 amRNSRedx to present two posters at AACR 2019
28th Feb 20197:00 amRNSIssue of Warrants and Change to Lease Agreement
14th Feb 20197:00 amRNSDirectorate Update
12th Feb 20197:00 amRNSNew in vivo data on ROCK2
6th Feb 201911:25 amRNSReceipt of Outstanding Loan
31st Jan 20197:00 amRNSDeinove return rights to Redx Programme
23rd Jan 201911:25 amRNSResults of Annual General Meeting
21st Jan 20197:00 amRNSRXC004 Trial Approval
10th Jan 20192:05 pmRNSSecond Price Monitoring Extn
10th Jan 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.